Aeglea Bio Therapeutics Inc represents a commitment to innovation, scientific excellence, and improving patients' lives. With a focus on developing transformative therapies, Aeglea Bio Therapeutics is dedicated to addressing unmet medical needs in the field of rare genetic diseases. The company's corporate philosophy revolves around leveraging their expertise in human enzyme biology to develop novel therapeutic solutions. Aeglea Bio Therapeutics believes in fostering strong collaborations, utilizing cutting-edge technologies, and advancing patient-centric approaches. By combining their passion for scientific discovery with a patient-driven mindset, Aeglea Bio Therapeutics strives to make a meaningful impact in the lives of individuals affected by rare diseases.

Aeglea Bio Therapeutics Inc is primarily present in the United States of America.

Aeglea Bio Therapeutics Inc has achieved significant milestones since its inception. Notably, the company successfully completed a Phase 1 clinical trial for its lead product candidate, AEB1102, demonstrating its safety and tolerability. Aeglea also received Fast Track Designation from the FDA for AEB1102 in combination with pembrolizumab for the treatment of cancer. In addition, the company expanded its pipeline by initiating a Phase 1/2 trial for AEB3103 in patients with Arginase 1 Deficiency, a rare genetic disorder. These achievements highlight Aeglea Bio Therapeutics Inc's commitment to developing innovative therapies and addressing unmet medical needs.

Aeglea Bio Therapeutics Inc, a leading biotechnology company, was founded in 2013 and is headquartered in Austin, Texas. The company focuses on developing innovative therapeutics to improve the lives of patients with rare genetic diseases and cancer. Aeglea Bio Therapeutics utilizes its proprietary technology platform, known as Aeglea's Engineered Human Enzyme Products (HEPs), to design and manufacture therapeutic enzymes. These enzymes are developed to target and degrade specific amino acids in the body, addressing the underlying metabolic imbalances associated with certain diseases. With a strong research and development pipeline, Aeglea Bio Therapeutics aims to provide patients with breakthrough treatments that have the potential to transform their lives.

The main competitors of Aeglea Bio Therapeutics Inc in the market include companies such as Amgen, Incyte Corporation, and bluebird bio. These companies operate in the biopharmaceutical industry and also focus on the development of innovative therapies and treatments. Aeglea Bio Therapeutics Inc, based in the United States, is known for its research in the field of human biochemistry and genetic insights to develop transformative medicines. As it continues to strive for advancements in the industry, it faces competition from these industry leaders in delivering cutting-edge solutions for various diseases and medical conditions.

Aeglea Bio Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

Aeglea Bio Therapeutics Inc is a biotechnology company with a unique business model focused on developing therapeutic enzymes to treat rare genetic diseases and certain cancers. By leveraging its proprietary technology platform, Aeglea engineers enzymes to degrade specific amino acids in the body associated with these diseases, aiming to restore balance and improve patient outcomes. Through targeted enzyme therapy, Aeglea seeks to address significant unmet medical needs and create value for patients, healthcare providers, and shareholders.

P/E odnos Aeglea Bio Therapeutics iznosi -14,03.

KUV kompanije Aeglea Bio Therapeutics iznosi 9,85.

AlleAktien kvalitativni skor za Aeglea Bio Therapeutics je 1/10.

očekivana Aeglea Bio Therapeutics promet je 13,60 mil. USD.

Dobit očekivana Aeglea Bio Therapeutics je -9,55 mil. USD.

Aeglea Bio Therapeutics Inc. is an innovative biotechnology company based in Austin, Texas. The company was founded in 2013 and specializes in the development of therapies for rare genetic disorders. Aeglea Bio Therapeutics has a unique business model based on two pillars: the development of new drugs and collaboration with other companies and research institutions. The first pillar of Aeglea Bio Therapeutics' business model is the development of therapies for rare genetic disorders. This is achieved through the research of the role of amino acids in metabolism and their effects on specific diseases. The company utilizes innovative technologies to identify and develop new treatment approaches. This includes the production of enzymes that selectively break down certain amino acids, thereby reducing or removing disease-causing substances. The first drug developed by Aeglea Bio Therapeutics is Pegzilarginase (AEB1102), an enzyme replacement therapy for the treatment of Arginase-1 deficiency, a rare genetic disease. The second pillar of Aeglea Bio Therapeutics' business model is collaboration with other companies and research institutions. The company works with various partners in the field of research and development to accelerate the development of new drugs. Aeglea Bio Therapeutics also collaborates with biopharmaceutical companies and other organizations to bring its technologies and products to market. For example, the company has announced a partnership with Merck Sharp & Dohme Corp. (MSD) to develop combination therapy for the treatment of certain types of cancer. Aeglea Bio Therapeutics currently offers only one product, Pegzilarginase (AEB1102), which is in the clinical phase. However, the company plans to expand its portfolio by developing additional enzyme replacement therapies and treating a broader range of genetic disorders. The company has also developed a diagnostic test for quick and easy diagnosis of Arginase-1 deficiency. The business model of Aeglea Bio Therapeutics is focused on developing and commercializing innovative therapies for rare genetic disorders. The company relies on close collaboration with other partners in the field of research and development and the use of innovative technologies.

Aeglea Bio Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Aeglea Bio Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Aeglea Bio Therapeutics je US00773J1034.

WKN od Aeglea Bio Therapeutics je A2AG5H.

Oznaka za praćenje akcija kompanije Aeglea Bio Therapeutics je AGLE.

U poslednjih 12 meseci, Aeglea Bio Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Aeglea Bio Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Aeglea Bio Therapeutics trenutno iznosi .

Aeglea Bio Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Aeglea Bio Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Aeglea Bio Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Aeglea Bio Therapeutics od 3. 11. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 3. 11. 2024..

Isplata poslednje dividende izvršena je 3. 11. 2024..

U godini 2023 kompanija Aeglea Bio Therapeutics je isplatila 0 USD kao dividende.

Dividende od Aeglea Bio Therapeutics se isplaćuju u USD.